New York—Determining which breast cancer patients receiving neoadjuvant chemotherapy should receive radiation is a bit tricky, when most of the data used to guide decision making come from an era when patients had surgery before their disease was altered by chemotherapy.
“Now when patients get chemotherapy up front, we have to backtrack and figure out what would have been their pathologic stage initially and what we should do if the patient has a pathologic complete response in the